NO831565L - HIGH-DERIVATIVE ISOMERS OF DERIVATIVES OF 1-AZA-BICYCLO- (2,2,2) -OCTAN AND PROCEDURE FOR THEIR PREPARATION - Google Patents
HIGH-DERIVATIVE ISOMERS OF DERIVATIVES OF 1-AZA-BICYCLO- (2,2,2) -OCTAN AND PROCEDURE FOR THEIR PREPARATIONInfo
- Publication number
- NO831565L NO831565L NO831565A NO831565A NO831565L NO 831565 L NO831565 L NO 831565L NO 831565 A NO831565 A NO 831565A NO 831565 A NO831565 A NO 831565A NO 831565 L NO831565 L NO 831565L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- group
- active substance
- compound
- formula
- Prior art date
Links
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical class C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 11
- 238000002360 preparation method Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 206010022714 Intestinal ulcer Diseases 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 230000001262 anti-secretory effect Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- FJASYYACMTUWRJ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl benzenesulfonate Chemical compound C1N(CC2)CCC2C1OS(=O)(=O)C1=CC=CC=C1 FJASYYACMTUWRJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960000279 quinupramine Drugs 0.000 description 2
- JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- -1 5-[1-aza bicyclo(2,2,2)oct-3(S)-yl]-10,11-dihydro-5H-dibenz(b ,f) azepine Chemical compound 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Foreliggende oppfinnelse har til gjenstand høyredreiende isomerer tilsvarende racemiske forbindelser med formelen: The subject of the present invention is dextrorotatory isomers corresponding to racemic compounds with the formula:
hvori A er et svovelatom eller en -CH^-CH^-gruppe og X er et hydrogenatom eller en - SO^ N( CE^)^ gruppe. wherein A is a sulfur atom or a -CH^-CH^ group and X is a hydrogen atom or a -SO^ N(CE^)^ group.
Oppfinnelsen har også til gjenstand en fremgangsmåte for fremstilling av disse høyredreiende isomerer og deres bruk som medikamenter. The subject of the invention is also a method for the production of these dextrorotatory isomers and their use as drugs.
Racemiske forbindelser med formel (I) er kjente forbindelserRacemic compounds of formula (I) are known compounds
som har interessante farmakologiske egenskaper og som spesielt kan benyttes for behandling av mave- og tarmsår og som anti-depressive midler (jfr. FR PS 2 318 638 og 2 052 991). which have interesting pharmacological properties and which can especially be used for the treatment of stomach and intestinal ulcers and as anti-depressants (cf. FR PS 2 318 638 and 2 052 991).
Formel (I) har et asymmetrisk karbonatom, nemlig karbonatornet i 3-stilling i 1-aza bicyklo (2,2,2) oktanringen, og de rasemiske forbindelser som tilsvarer denne formel kan oppløses i to optiske enansiomorfer. Formula (I) has an asymmetric carbon atom, namely the carbon atom in the 3-position in the 1-aza bicyclo (2,2,2) octane ring, and the racemic compounds corresponding to this formula can be resolved into two optical enantiomorphs.
Forbindelsene ifølge oppfinnelsen som er de høyredreiende enan-siomorf er tilsvarer formelen: The compounds according to the invention which are dextrorotatory enantiomorphic correspond to the formula:
hvori A og X har samme betydning som i formel (I) og hvori den absolutte konfigurasjon av karbonatomet i 3-stilling i en aza-bicyklo (2,2,2) oktan ringen er sinister, (S). in which A and X have the same meaning as in formula (I) and in which the absolute configuration of the carbon atom in the 3-position in an aza-bicyclo (2,2,2) octane ring is sinister, (S).
Forbindelsene med formel (I a) kan fremstilles ved kondensering av 3(R)-fenyl-sulfonyloksy [1-aza bicyklo(2,2,2) oktan] med forbindelser med formelen: The compounds of formula (I a) can be prepared by condensation of 3(R)-phenyl-sulfonyloxy [1-aza bicyclo(2,2,2)octane] with compounds of the formula:
hvori A og X har samme betydning som i formel (I), i henhold til en prosess analog den som er beskrevet i de ovenfor angitte franske patenter for fremstilling av forbindelser med formelen (I) fra racemisk 3-fenylsulfonyloksy [1-aza bicyklo(2,2,2)oktan] og forbindelser med formel (II). Et slikt kondensasjon kan gjennomføres f. eks. i et inert oppløsningsmiddel slik som et aromatisk hydrokarbon (toluen, xylen osv.) eller en blanding av et aromatisk hydrokarbon og et aprotisk polart oppløsnings-middel (f. eks. heksametylfosfortriamid), i nærvær av natrium hydrid, ved temperaturer på 8 0 - 110°C. wherein A and X have the same meanings as in formula (I), according to a process analogous to that described in the above-mentioned French patents for the preparation of compounds of formula (I) from racemic 3-phenylsulfonyloxy [1-aza bicyclo( 2,2,2)octane] and compounds of formula (II). Such condensation can be carried out e.g. in an inert solvent such as an aromatic hydrocarbon (toluene, xylene, etc.) or a mixture of an aromatic hydrocarbon and an aprotic polar solvent (e.g. hexamethylphosphoric triamide), in the presence of sodium hydride, at temperatures of 80 - 110°C.
Forbindelsene (Ia) som oppnås i ren tilstand ved fremgangsmåten som tidligere er beskrevet kan renses ved klassiske metoder, enten fysikalske som krystallisering eller kromatografi, eller kjemiske som dannelse av salter og regenerering av basen ved behandling av saltene i et alkalisk medium. The compounds (Ia) obtained in a pure state by the method previously described can be purified by classical methods, either physical such as crystallization or chromatography, or chemical such as formation of salts and regeneration of the base by treating the salts in an alkaline medium.
Forbindelsene (Ia) i form av frie baser kan omdannes til addi-sjon salter med mineral- eller organiske syrer, ved hjelp av en slik syre i et egnet oppløsningsmiddel. The compounds (Ia) in the form of free bases can be converted into addition salts with mineral or organic acids, using such an acid in a suitable solvent.
De høyredreiende enansiomorfer méd formel (1a) viser i farmakologiske i forbindelse med den terapeutiske anvendelse av race mater med formel (I) en aktivitet som er overlegen den for de sistnevnte. De har en distinkt fordel i forhold til de tilsvarende racemater fordi de tillater å oppnå en ekvivalent terapeutisk virkning med lavere dose. Et slikt resultat var uventet. The dextrorotatory enantiomorphs with formula (1a) show pharmacologically in connection with the therapeutic use of race mater with formula (I) an activity which is superior to that of the latter. They have a distinct advantage over the corresponding racemates because they allow an equivalent therapeutic effect to be achieved with a lower dose. Such a result was unexpected.
De følgende eksempler viser oppfinnelsen uten å begrense den. The following examples illustrate the invention without limiting it.
Eksempel 1 : N^. NzdimetYl_10-_.[ lzaza_bicYk!2i^ii^]_gct=3j[ 5 )_=y1I Example 1 : N^. NzdimetYl_10-_.[ lzaza_bicYk!2i^ii^]_gct=3j[ 5 )_=y1I
1.0_H-f enotiaz'in_2-sulf onamid.1.0_H-f enotiaz'in_2-sulfonamide.
15,3 g N.N-dimetyl fenotiazin 2-sulfonamid og 160 ml vannfri xylen anbringes i en nitrogenajbmosfære. 1,5 g 80 %-ig natrium hydrid i olje og 50 ml hexametylforsfortriamid tilsettes. Blandingen bringes til 80°C og en oppløsning av 9,2 g 3(R)-fenylsulfonyloksy [1-aza bicyklo(2,2,2) oktan] i 60 ml vannfri xylen tilsettes. Etter omrøring i 20 timer avkjøles det hele, 50 ml vann tilsettes, blandingen dekanteres og den vandige fase ekstraheres med 50 ml etylacetat. Den organiske fase, etylacetatfasen, ekstraheres 3 ganger, hver gang med 50 ml av en N vandig oppløsning av metansulfonsyre og to ganger med 50 ml vann hver gang. Den samlede vandige fase vaskes med 150 ml eter og deretter gjøres mediet alkalisk ved tilsetning av 12,5 ml av en konsentrert ammoniakkoppløsning hvoretter oljen som separeres ut ekstraheres tre ganger, hver gang med 100 ml etylen acetat. Den organiske fase vaskes ved 50 ml vann, tørkes over magnesiumsulfat og fordampes til tørr tilstand under redusert trykk. 6,8 g produkt oppnås og dette omkrystalliseres fra 50 ml aceton. På denne måte oppnås 4,9 g N.N-dimetyl 10-[1-aza bicyklo(2,2,2)oct-3(S)-yl] 10 H-fenotiazin 2-sulfonamid som smelter ved 201°C. Etter 2 krystalliseringer fra metanol oppnås 2,6 g N.N-dimetyl 10-[1-aza bicyklo(2,2,2)oct-3(S)-yl] 10H-fenotiazin'2-sulfonamid som har følgende egenskaper: 15.3 g of N.N-dimethyl phenothiazine 2-sulfonamide and 160 ml of anhydrous xylene are placed in a nitrogen atmosphere. 1.5 g of 80% sodium hydride in oil and 50 ml of hexamethylforsfortriamide are added. The mixture is brought to 80°C and a solution of 9.2 g of 3(R)-phenylsulfonyloxy [1-aza bicyclo(2,2,2)octane] in 60 ml of anhydrous xylene is added. After stirring for 20 hours, the whole is cooled, 50 ml of water is added, the mixture is decanted and the aqueous phase is extracted with 50 ml of ethyl acetate. The organic phase, the ethyl acetate phase, is extracted 3 times, each time with 50 ml of an N aqueous solution of methanesulfonic acid and twice with 50 ml of water each time. The combined aqueous phase is washed with 150 ml of ether and then the medium is made alkaline by the addition of 12.5 ml of a concentrated ammonia solution, after which the oil that separates out is extracted three times, each time with 100 ml of ethylene acetate. The organic phase is washed with 50 ml of water, dried over magnesium sulphate and evaporated to dryness under reduced pressure. 6.8 g of product are obtained and this is recrystallized from 50 ml of acetone. In this way, 4.9 g of N.N-dimethyl 10-[1-aza bicyclo(2,2,2)oct-3(S)-yl] 10 H-phenothiazine 2-sulfonamide are obtained which melts at 201°C. After 2 crystallizations from methanol, 2.6 g of N.N-dimethyl 10-[1-aza bicyclo(2,2,2)oct-3(S)-yl] 10H-phenothiazine'2-sulfonamide are obtained, which have the following properties:
smeltepunkt 201°Cmelting point 201°C
spesifikk rotasjonsevne (målt på en 1%-ig opp- specific rotation capacity (measured on a 1% up-
løsning av produktet i en N vandig oppløsning av metan-sulfonsyre): optisk renhet (bestemt ved den kalorimetriske metode som er beskrevet av C. Fouquey og J. Jacques i Tetra-hedron, 23, (1967), 4009): solution of the product in an N aqueous solution of methanesulfonic acid): optical purity (determined by the calorimetric method described by C. Fouquey and J. Jacques in Tetrahedron, 23, (1967), 4009):
3(R)-fenyl-sulfonyl-oksy [1-aza bicyklo(2,2,2)oktan] kan fremstilles ved hjelp av benzen-sulfonyl klorid på [1-aza bicyklo (2,2,2)oktan]-3(R)-ol i et medium av et klorert oppløsnings-middel i henhold til den metode som er identisk med den som 3(R)-phenyl-sulfonyl-oxy [1-aza bicyclo(2,2,2)octane] can be prepared by means of benzenesulfonyl chloride on [1-aza bicyclo (2,2,2)octane]-3 (R)-ol in a medium of a chlorinated solvent according to the method identical to that which
ble benyttet av E. E. Mikhlina et al. (J. Gen. Chem. USSR, 30, was used by E.E. Mikhlina et al. (J. Gen. Chem. USSR, 30,
(1960), 2953-8) for fremstilling av racemisk 3-fenyl-sulfonyl-oksy [1-aza bicyklo(2,2,2)oktan] ut fra et racemisk [1-aza bicyklo ( 2 , 2 , 2 ) oktan] -3-ol . 3(R)-fenylsulfonyl-oksy [1-aza bicyklo ( 2 , 2 , 2) oktan] har følgende karakteristika: (1960), 2953-8) for the preparation of racemic 3-phenyl-sulfonyl-oxy [1-aza bicyclo(2,2,2)octane] from a racemic [1-aza bicyclo ( 2 , 2 , 2 ) octane ] -3-ol. 3(R)-phenylsulfonyl-oxy [1-aza bicyclo (2,2,2)octane] has the following characteristics:
smeltepunkt < 50°Cmelting point < 50°C
Spesifikk rotasjonsevne (målt i en 3%-ig opp-løsning av produktet i en N vandig oppløsning av saltsyre): Specific rotatability (measured in a 3% solution of the product in an N aqueous solution of hydrochloric acid):
[1-aza bicyklo(2,2,2)oktan]-3(R)-ol kan fremstilles som antydet av B. Ringdahl et al. i Acta Pharm Sued. , J_6 (1 979), 2.8.1.. [1-aza bicyclo(2,2,2)octane]-3(R)-ol can be prepared as suggested by B. Ringdahl et al. in Acta Pharm Sued. , J_6 (1 979), 2.8.1..
Eksempel 2: ^ zLlz^^ J°i£Y^ l2iZi. Ij. Ziqct2^ i5lzYllzl2jLllz§:ihY^ 2Z Example 2: ^ zLlz^^ J°i£Y^ l2iZi. Ouch. Ziqct2^ i5lzYllzl2jLllz§:ihY^ 2Z
å3ldibenz__(bif )__azep_inå3ldibenz__(bif )__azep_in
4,5 g 3(R)-fenyl-sulfonyl-oksy [1-aza bicyklo(2,2,2)oktan], 0,75 g 80 %-ig natriumhydrid i olje og 40 ml vannfri toluen 4.5 g 3(R)-phenyl-sulfonyl-oxy [1-aza bicyclo(2,2,2)octane], 0.75 g 80% sodium hydride in oil and 40 ml anhydrous toluene
bringes under en nitrogenatmosfære. Blandingen bringes til 105 - 110°C og en oppløsning av 4,2 g 10,11-dihydro 5H-dibenz (b,f) azepin og 3 ml N-metyl 2-pyrrolidone i 15 ml vannfri toluen tilsettes i løpet av 2 timer. Blandigen holdes ved 105 - 110°C i ytterligere 30 minutter, avkjøles deretter og 2 ml etanol og 20 ml vann tilsettes. Etter dekantering ekstraheres den vandige fase med 20 ml toluen. Den organiske fase ekstraheres to ganger med 20 ml av en vandig oppløsning av metan-sulfonsyre hver gang og deretter tre ganger med 10 ml vann hver gang. De samlede vandige faser gjøres alkaliske ved tilsetning av 3,5 ml av en konsentrert ammoniakkoppløsning og oljen som separeres ut ekstraheres 5 ganger med 50 ml toluen hver gang. Den organiske fase"tørkes over magnesiumsulfat og fordampes til tørr tilstand under redusert trykk. Resten som oppnås, 3,1 g, fikseres på en kolonne av silicagel og elueres deretter med en blanding av 9 7 volumdeler kloroform og 3 volumdeler dietylamin. Det gjenvinnes således 2,6 g produkt i uren form og dette krystalliseres fra 3 ml acetonitril. Man oppnår på denne måte 2,2 g 5-[1-aza bicyklo(2,2,2)oct-3(S)-yl] -10,11-dihydro-5H-dibenz(b,f) azepin med. følgende karakteristika: brought under a nitrogen atmosphere. The mixture is brought to 105 - 110°C and a solution of 4.2 g of 10,11-dihydro 5H-dibenz (b,f) azepine and 3 ml of N-methyl 2-pyrrolidone in 15 ml of anhydrous toluene is added over the course of 2 hours . The mixture is kept at 105 - 110°C for a further 30 minutes, then cooled and 2 ml of ethanol and 20 ml of water are added. After decantation, the aqueous phase is extracted with 20 ml of toluene. The organic phase is extracted twice with 20 ml of an aqueous solution of methanesulfonic acid each time and then three times with 10 ml of water each time. The combined aqueous phases are made alkaline by the addition of 3.5 ml of a concentrated ammonia solution and the oil which separates out is extracted 5 times with 50 ml of toluene each time. The organic phase is dried over magnesium sulfate and evaporated to dryness under reduced pressure. The residue obtained, 3.1 g, is fixed on a column of silica gel and then eluted with a mixture of 97 parts by volume of chloroform and 3 parts by volume of diethylamine. It is thus recovered 2.6 g of product in impure form and this is crystallized from 3 ml of acetonitrile.In this way, 2.2 g of 5-[1-azabicyclo(2,2,2)oct-3(S)-yl]-10 is obtained ,11-dihydro-5H-dibenz(b,f)azepine with the following characteristics:
smeltepunkt: 144-145°Cmelting point: 144-145°C
spesifikk rotasjonsevne (målt på en 3 %-ig oppløsning av produktet i en N vandig opp-løsning av metan-sulfonsyre): specific rotatability (measured on a 3% solution of the product in an N aqueous solution of methanesulfonic acid):
optisk renhet (bestemt ved den ovenfor antydede metode): > 95%. optical purity (determined by the method indicated above): > 95%.
Etter omkrystallisering av dette produkt 3 ganger fra acetonitril oppnås 0,6 g ren 5-[1-aza bicyklo(2,2,2)oct-3(S)-yl]-10,11-dihydro-5H-dibenz(b,f) azepin med smeltepunkt 146 - 147°C og en optisk renhet, bestemt ved den ovenfor antydede metode, på 99% og med en spesifikk rotasjonsevne (målt på en 1 %-ig oppløsning av produktet i N metan-sulfonsyre) på After recrystallization of this product 3 times from acetonitrile, 0.6 g of pure 5-[1-aza bicyclo(2,2,2)oct-3(S)-yl]-10,11-dihydro-5H-dibenz(b ,f) azepine with a melting point of 146 - 147°C and an optical purity, determined by the method indicated above, of 99% and with a specific rotatability (measured on a 1% solution of the product in N methanesulfonic acid) of
Farmakologiske egenskaper. Pharmacological properties.
1. Anti- sekretorisk virkning:1. Anti-secretory action:
Den inhiberende aktivitet for mavesyresekresjon for forbindelsen i eksempel 1 sammenlignet med den for det tilsvarende racemat ved bruk av mavehypersekresjon stimulert av pentagastrin hos hunder med en Heidenheim pose. Tre bastarder utstyrt med en Heidenheim pose og som hadde fastet i 18 timer fikk i løpet av 4 timer 4 mg/kg/time pentagastrin i et volum på 30 ml/time ved venøs perfusjon. Sekresjonen i posen samles i en kolbe som byttes hvert kvarter. 1j time etter perfusjonsstart inngis produktet som skal studeres via oral vei i en gelatin tablett nr. 000. 50% effektiv dose ED50, er den dose av produktet som med 50% reduserer syreutskillelse/time, notert under den 3. og 4. forsøkstime, sammenlignet med utskilling/time den 2. perfu-sjonstime. The gastric acid secretion inhibitory activity of the compound of Example 1 compared with that of the corresponding racemate using gastric hypersecretion stimulated by pentagastrin in dogs with a Heidenheim pouch. Three bastards equipped with a Heidenheim bag and which had fasted for 18 hours received 4 mg/kg/hour pentagastrin in a volume of 30 ml/hour by venous perfusion during 4 hours. The secretion in the bag is collected in a flask which is changed every fifteen minutes. 1 hour after the start of perfusion, the product to be studied is administered orally in a gelatin tablet no. 000. 50% effective dose ED50 is the dose of the product which reduces acid secretion/hour by 50%, noted during the 3rd and 4th experimental hour, compared to excretion/hour on the 2nd perfusion hour.
De oppnådde resultater oppsummeres i den følgende tabell der dosene er uttrykt for produktet i form av basen: The results obtained are summarized in the following table where the doses are expressed for the product in terms of the base:
Den inhiberende virkning for mavesyresekresjon for forbindelsen The inhibitory effect on gastric acid secretion for the compound
i eksempel 1 er derfor overlegen den til det tilsvarende racemat. in example 1 is therefore superior to that of the corresponding racemate.
2. Anti- depressiv virkning:2. Anti-depressant effect:
Den anti-depressive virkning for quinupramin er relatert blokkeringen av sentral muskarin reseptorer (jfr. G. Le Fur iEncephalon, 6_, 303 , (1 980)) og den anti-depressive virkning for forbindelsen i eksempel 2 ble sammenlignet med den for det tilsvarende racemat (quinupramin) ved måling av de respektive affiniteter av disse produkter for muskarin reseptorer av ace-tyl-koline. Disse affiniteter ble bestemt før måling av kapa-siteten for produktet for å fortrenge tritsiert benzilat av 3-quinuklidinol ( 3H-QNB) fra bindingspunktet og uttrykkes som verdien ICj-q som er den konsentrasjon av produktet (inanomol per liter) som er nødvendig for å oppnå en 50% inhibering av bindingen av<3>H-QNB. Målingene ble gjennomført i henhold til den metode som er beskrevet av H.I. Yamamura et al., Proe. Nat. Acad.Sci. (USA), 7J_, 1 725 (1 974) ved bruk av membraner fra hjerne striatum hos rotter. The anti-depressant effect of quinupramine is related to the blocking of central muscarinic receptors (cf. G. Le Fur iEncephalon, 6_, 303 , (1 980)) and the anti-depressant effect of the compound in example 2 was compared with that of the corresponding racemate (quinupramine) by measuring the respective affinities of these products for muscarinic receptors of acetyl-choline. These affinities were determined before measuring the capacity of the product to displace tritiated benzilate of 3-quinuclidinol (3H-QNB) from the binding site and are expressed as the value ICj-q which is the concentration of the product (inanomoles per liter) necessary for to achieve a 50% inhibition of the binding of<3>H-QNB. The measurements were carried out according to the method described by H.I. Yamamura et al., Proe. Nat. Acad.Sci. (USA), 7J_, 1725 (1974) using membranes from rat brain striatum.
De oppnådde resultater er oppsummert i følgende tabell: The results obtained are summarized in the following table:
Forbindelsen ifølge eksempel 2 er derfor to ganger så aktivt som det tilsvarende racemat. The compound according to example 2 is therefore twice as active as the corresponding racemate.
Toksikologiske egenskaper.Toxicological properties.
Den akutte giftighet for forbindelsene med formel (Ia) er så og si de samme som for det tilsvarende racemat. The acute toxicity of the compounds of formula (Ia) is more or less the same as that of the corresponding racemate.
Therapeutisk anvendelse.Therapeutic application.
Forbindelser med formel (Ia) og deres salter med farmasøytisk akseptable syrer kan benyttes i humanterapien som aktiv stoff-er for medikamenter, spesielt anti-depresjonsmedikamenter og anti-sekretoriske medikamenter for behandling av mave- og tarmsår. Compounds of formula (Ia) and their salts with pharmaceutically acceptable acids can be used in human therapy as active substances for drugs, especially anti-depressant drugs and anti-secretory drugs for the treatment of stomach and intestinal ulcers.
Et slikt medikament inneholder i tillegg til det aktive materi-alet en farmasøytisk akseptabel bærer slik som de som vanligvis benyttes på det farmasøytiske område og kan presenteres i form av tabletter, kapsler, gelatinkapsler, suppositorier, spise-lige og injiserbare oppløsninger osv. Such a drug contains, in addition to the active material, a pharmaceutically acceptable carrier such as those usually used in the pharmaceutical field and can be presented in the form of tablets, capsules, gelatin capsules, suppositories, edible and injectable solutions, etc.
Doseringen avhenger av den ønskede virkning og inngivelses-metoden. Ad oral vei er den generelt for eksempel mellom 10 og 200 mg pr. dag av den aktive substans for en voksen person. The dosage depends on the desired effect and the method of administration. By oral route, it is generally, for example, between 10 and 200 mg per day of the active substance for an adult.
Claims (7)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8207703A FR2526433B1 (en) | 1982-05-04 | 1982-05-04 | DEXTROGYRIC ISOMERS OF AZA-1 BICYCLO (2,2,2) OCTANE DERIVATIVES, THEIR PREPARATION METHOD AND MEDICAMENTS CONTAINING THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
NO831565L true NO831565L (en) | 1983-11-07 |
Family
ID=9273691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO831565A NO831565L (en) | 1982-05-04 | 1983-05-03 | HIGH-DERIVATIVE ISOMERS OF DERIVATIVES OF 1-AZA-BICYCLO- (2,2,2) -OCTAN AND PROCEDURE FOR THEIR PREPARATION |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0093643A1 (en) |
JP (1) | JPS58203990A (en) |
AU (1) | AU1419383A (en) |
DK (1) | DK197583A (en) |
ES (1) | ES8407035A1 (en) |
FR (1) | FR2526433B1 (en) |
GR (1) | GR72287B (en) |
IL (1) | IL68264A0 (en) |
MA (1) | MA19786A1 (en) |
NO (1) | NO831565L (en) |
PT (1) | PT76487B (en) |
ZA (1) | ZA833137B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3789039T2 (en) * | 1986-06-27 | 1994-06-09 | Beecham Group Plc | Bridged bicyclic N-heterocyclic compounds. |
GB8615785D0 (en) * | 1986-06-27 | 1986-08-06 | Beecham Group Plc | Compounds |
IT1251161B (en) * | 1991-08-07 | 1995-05-04 | QUATERNARY AMMONIUM DERIVATIVES OF (-) AND (+) - 3- (10 H-PHENOTHIAZIN-10-ILMETHYL) -L-AZABICYCLE (2.2.2.) OCT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1250534A (en) * | 1969-03-03 | 1971-10-20 | ||
FR2052991A1 (en) * | 1969-06-20 | 1971-04-16 | Sogeras | N-(dibenzo (bf) azepines quinuclidines |
FR2318638A2 (en) * | 1975-07-25 | 1977-02-18 | Sogeras | NEW DERIVATIVES OF PHENOTHIAZINE AND PROCESS FOR THEIR PREPARATION |
-
1982
- 1982-05-04 FR FR8207703A patent/FR2526433B1/en not_active Expired
-
1983
- 1983-03-28 IL IL68264A patent/IL68264A0/en unknown
- 1983-03-31 PT PT76487A patent/PT76487B/en unknown
- 1983-04-13 GR GR71071A patent/GR72287B/el unknown
- 1983-04-22 EP EP83400801A patent/EP0093643A1/en not_active Withdrawn
- 1983-04-28 MA MA20006A patent/MA19786A1/en unknown
- 1983-05-02 JP JP58076351A patent/JPS58203990A/en active Pending
- 1983-05-03 ES ES522063A patent/ES8407035A1/en not_active Expired
- 1983-05-03 NO NO831565A patent/NO831565L/en unknown
- 1983-05-03 AU AU14193/83A patent/AU1419383A/en not_active Abandoned
- 1983-05-03 ZA ZA833137A patent/ZA833137B/en unknown
- 1983-05-03 DK DK197583A patent/DK197583A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK197583A (en) | 1983-11-05 |
FR2526433A1 (en) | 1983-11-10 |
ES522063A0 (en) | 1984-09-01 |
PT76487A (en) | 1983-04-01 |
EP0093643A1 (en) | 1983-11-09 |
MA19786A1 (en) | 1983-12-31 |
IL68264A0 (en) | 1983-06-15 |
AU1419383A (en) | 1983-11-17 |
GR72287B (en) | 1983-10-17 |
JPS58203990A (en) | 1983-11-28 |
ZA833137B (en) | 1984-01-25 |
FR2526433B1 (en) | 1985-10-18 |
DK197583D0 (en) | 1983-05-03 |
ES8407035A1 (en) | 1984-09-01 |
PT76487B (en) | 1985-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI95464B (en) | Process for the preparation of a therapeutically useful 4- (di-n-propyl) amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo / c, d / indole hippurate | |
DK159441B (en) | 11-SUBSTITUTED 5,11-DIHYDRO-6H-DIBENZ (B, E) AZEPIN-6-ON DERIVATIVES, MEDICINALS CONTAINING THESE COMPOUNDS AND ANALOGY PROCEDURE FOR THE PREPARATION OF THE COMPOUNDS | |
US3379729A (en) | Piperazinyldibenzothiepins | |
NO831565L (en) | HIGH-DERIVATIVE ISOMERS OF DERIVATIVES OF 1-AZA-BICYCLO- (2,2,2) -OCTAN AND PROCEDURE FOR THEIR PREPARATION | |
GB2142332A (en) | Spirosuccinimide derivatives | |
GB2120662A (en) | New azepinoindoles, their production and pharmaceutical compositions containing them | |
CH637653A5 (en) | 5,11-DIHYDRO-6H-PYRIDO (2,3-B) (1,4) BENZODIAZEPINE-6-ONE SUBSTITUTED IN 11-POSITION, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS. | |
NO174053B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE R (-) 3-KINUCLIDINOL DERIVATIVES | |
US4668674A (en) | (+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo[b,][1,4]diazepin-11-one, the isolation thereof and its use as a pharmaceutical material | |
JPH01313477A (en) | Production of indole-3-carboxylic ester of trans-hexahydro-8-hydroxy-2, 6-methano-2h- quinolidine-3-(4h)-one | |
CA1161857A (en) | 3-amino-1-benzoxepin derivatives, their salts and pharmaceutical compositions thereof and process for their preparation | |
US3086972A (en) | Aza-thiaxanthene derivatives | |
CA1069506A (en) | Dibenzo (b,f) thiepin derivative | |
US4206210A (en) | Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity | |
CA1090334A (en) | Alkylthio-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro- 1h-3-benzazepines having dopaminergic activity | |
JPH03501389A (en) | Novel thienyloxy-alkylamine derivative, process for its production and pharmaceutical containing this compound | |
US4031225A (en) | 4H-Benzo[4,5]cyclohepta[1,2-b]thiophenes | |
JPS60116678A (en) | N-propanol amine derivative ether | |
EP0043729B1 (en) | New dopaminergic isoquinolines | |
US3564015A (en) | Derivatives of dibenzocycloheptenes | |
JPS58148883A (en) | Pyridobenzodiazepinone compound | |
JPS62425A (en) | Medicinal composition | |
EP0573548B1 (en) | Neuroprotectant agents | |
KR850000062B1 (en) | Process for preparing amidines | |
JPS62158265A (en) | Optically active 2-chloro-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo (d,g)(1,3,6)dioxazocine |